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Abstract
The eﬃcacy, safety, and tolerability of Lu AA21004 vs. placebo using venlafaxine XR as active reference in
patients with DSM-IV-TR major depressive disorder (MDD) were evaluated. Lu AA21004 is a novel
antidepressant that is a 5-HT3 and 5-HT7 receptor antagonist, 5-HT1A receptor agonist, 5-HT1B receptor
partial agonist and inhibitor of the 5-HT transporter in recombinant cell lines. In this 6-wk, multi-site
study, 429 patients were randomly assigned (1:1:1:1) to 5 or 10 mg Lu AA21004, placebo or 225 mg
venlafaxine XR. All patients had a baseline Montgomery–A ˚ sberg Depression Rating Scale (MADRS) total
score o30. The primary eﬃcacy analysis was based on the MADRS total score adjusting for multiplicity
using a hierarchical testing procedure starting with the highest dose vs. placebo. Lu AA21004 was
statistically signiﬁcantly superior to placebo (n=105) in mean change from baseline in MADRS total score
at week 6 (p<0.0001, last observation carried forward), with a mean treatment diﬀerence vs. placebo of 5.9
(5 mg, n=108), and 5.7 (10 mg, n=100) points. Venlafaxine XR (n=112) was also signiﬁcantly superior to
placebo at week 6 (p<0.0001). In total, 30 patients withdrew due to adverse events (AEs) – placebo: four
(4%); 5 mg Lu AA21004: three (3%); 10 mg Lu AA21004: seven (7%); and venlafaxine: 16 (14%). The
most common AEs were nausea, headache, hyperhidrosis, and dry mouth. No clinically relevant changes
over time were seen in the clinical laboratory results, vital signs, weight, or ECG parameters. In this study,
treatment with 5 mg and 10 mg Lu AA21004 for 6 wk was eﬃcacious and well tolerated in patients
with MDD.
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Introduction
Lu AA21004 (1-[2-(2,4-dimethyl-phenylsulfanyl)-
phenyl]-piperazine) is a novel compound under de-
velopment as an antidepressant (Bang-Andersen et al.
2011) with aﬃnity for the human 5-HT1A, 5-HT1B,
5-HT3 and 5-HT7 receptors and the 5-HT transporter
(SERT) (Moore et al. 2008). Based on preclinical data,
these aﬃnities are considered to be of clinical rel-
evance and involved in the mechanism of action at
therapeutic doses. In vivo, Lu AA21004 increases the
extracellular levels of serotonin (5-HT), noradrenaline,
dopamine, acetylcholine and histamine in rat pre-
frontal cortex and hippocampus (Moore et al. 2008).
Lu AA21004 is extensively metabolized in the liver
and at least ﬁve cytochrome P450 isoenzymes appear
to be involved. The metabolism of Lu AA21004 to
its major metabolite (pharmacologically inactive) is
mediated primarily by CYP2D6. In addition, Lu
AA21004 does not seem to be a clinically relevant
inhibitor or inducer of cytochrome P450 isoenzymes.
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ARTICLEThe terminal elimination half-life after multiple doses
is estimated at y60–70 h. The exposure (Cmax and area
under curve) increased linearly with dose (2.5–60 mg).
The absorption of Lu AA21004 is independent of
food intake (Wang et al. 2009) and maximum plasma
concentrations are reached 3–16 h after dosing. The
rationale for choosing the Lu AA21004 doses (5 and
10 mg) in this proof-of-concept study was based on
non-clinical and phase I data. Approximately 60–80%
occupancy of the human SERT is required to achieve a
therapeutic eﬀect with selective serotonin reuptake
inhibitors (SSRIs) or serotonin noradrenaline reuptake
inhibitors (SNRIs) (Meyer, 2007). In contrast, an occu-
pancy level of 41% with Lu AA20004 in rats led to a
signiﬁcant increase in extracellular levels of 5-HT,
perhaps due to the additional pharmacological activi-
ties of Lu AA21004, which may counteract negative
feedback mechanisms operating at cellular and net-
work levels. The dose of 5 mg/d corresponds to a
SERT occupancy of y40% in human brain and was,
therefore, expected to be an eﬀective dose (Areberg
et al. 2009).
The aim of this phase II clinical study was to inves-
tigate the eﬃcacy, safety, and tolerability of two ﬁxed
doses (5 and 10 mg/d) of Lu AA21004 vs. that of
placebo after 6 wk treatment in adult patients with
major depressive disorder (MDD). Venlafaxine XR
(225 mg/d) was used as the active reference.
Method
This randomized, double-blind, ﬁxed-dose, placebo-
controlled, active reference study recruited 429 ran-
domized patients from 49 psychiatric settings in
11 countries (Australia, Austria, Canada, Czech
Republic, Finland, France, Italy, Malaysia, Slovakia,
Spain, Sweden). Outpatients with MDD were re-
cruited from psychiatric settings from August 2006 to
August 2007. Advertisements were used in Australia,
Austria, Canada, Finland, Malaysia, and Sweden. The
study was conducted in accordance with the prin-
ciples of Good Clinical Practice (ICH, 1996) and the
Declaration of Helsinki (WMA, 1964). Local ethics
committees approved the study design and eligible
patients gave their written informed consent before
participating.
Eligible patients were randomized equally
(1:1:1:1) to one of the four treatment arms for a 6-wk
double-blind treatment period. Randomized patients
were given 1-wk wallet cards at each visit and were
instructed to take two capsules per day, orally, at the
same time every day (preferably in the morning). Lu
AA21004 was dosed at 5 or 10 mg/d for 6 wk and
venlafaxine at 75 mg/d for 4 d, 150 mg/d for the fol-
lowing 3 d, and 225 mg/d for the remainder of the
treatment period. Eﬃcacy and tolerability were as-
sessed at screening, baseline and after 1, 2, 3, 4, 5, and
6 wk. Patients who completed the 6-wk double-blind
treatment period entered a 2-wk double-blind taper
period. During this period, patients on 5 mg/d Lu
AA21004 switched to placebo; patients on 10 mg/d Lu
AA21004 received 5 mg/d Lu AA21004 for the ﬁrst
week (week 7) and placebo for the second week
(week 8); patients on placebo remained on placebo;
patients on venlafaxine received 150 mg/d venlafax-
ine for the ﬁrst week (week 7) and 75 mg/d for the
second week (week 8). Patients were contacted for a
safety follow-up 4 wk after the completion visit.
Down-taper medication was also oﬀered to patients
who withdrew.
Main entry criteria
Patients with MDD presenting with a current major
depressive episode according to DSM-IV-TR criteria
(APA, 1994) were included in the study if they were an
outpatient of either sex, aged from 18 yr to 65 yr, with
a Montgomery–A ˚ sberg Depression Rating Scale
(MADRS) (Montgomery & A ˚ sberg, 1979) total score
o30 at the baseline visit.
Patients were excluded if they had any current
psychiatric disorder other than MDD as deﬁned in
DSM-IV-TR [assessed using the Mini International
Neuropsychiatric Interview (MINI; Sheehan et al.
1998)], or if they had a current or past history of manic
or hypomanic episode, schizophrenia or any other
psychotic disorder, including major depression with
psychotic features, mental retardation, organic mental
disorders, or mental disorders due to a general medi-
cal condition, any substance abuse disorder within the
previous 6 months, presence or history of a clinically
signiﬁcant neurological disorder (including epilepsy),
any neurodegenerative disorder, or any Axis II dis-
order that might compromise the study.
Patients at serious risk of suicide, based on the in-
vestigator’s clinical judgement, or who had a score of
o5 on item 10 of the MADRS scale (suicidal thoughts)
were also excluded, as were those receiving formal
behaviour therapy or systematic psychotherapy,
or were pregnant or breastfeeding, had a known
hypersensitivity or were non-response to venlafaxine,
or whose current depressive symptoms were con-
sidered by the investigator to have been resistant
to two adequate antidepressant treatments of at least
6 wk duration, or had previously been exposed to
Lu AA21004.
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following psychotropic drugs within 2 wk prior to
baseline or during the study: Reversible or irreversible
monoamine oxidase inhibitors, SSRIs (ﬂuoxetine
within 5 wk), SNRIs, tricyclic antidepressants, psy-
choactive herbal remedies, any drug used for aug-
mentation of antidepressant action or any other
antidepressant drugs, oral antipsychotic and anti-
manic drugs, or dopamine antagonists, any anxiolytics
(including benzodiazepines); and any anticonvulsant
drug, serotonergic agonists, narcotic analgesics or
cough agents, anti-arrhythmics, oral anticoagulants,
proton pump inhibitors, steroids, cisapride, macrolide
antibiotics, antifungal agents, antihypertensives,
all anti-inﬂammatory agents, anti-migraine agents,
pseudoephedrine, hypolipidaemics, and episodic use
of insulin. Occasional use of zolpidem, zopiclone and
zaleplon for insomnia was allowed.
Patients were withdrawn if they became pregnant
during the study, if the investigator considered it to be
in the best interest of the patient for safety/eﬃcacy
reasons, if laboratory values were outside normal
ranges and clinically signiﬁcant, if they were con-
sidered to be at signiﬁcant risk of suicide, if they
scored o5 points on item 10 (suicidal thoughts) of the
MADRS, if the randomization code for a patient was
broken, if consent to participate was withdrawn, if
they did not take study medication for more than
6 consecutive days, or if the patient was lost to follow-
up. The patient could be withdrawn from the study
if a serious adverse event (SAE) occurred. If adverse
events (AEs) were contributory to withdrawal, they
were always regarded as the primary reason for
withdrawal.
Eﬃcacy rating
Patients were evaluated using the MADRS from
baseline to week 6. Rater training was undertaken to
increase inter-rater reliability, and was chaired by an
experienced investigator. Only those investigators
who had actively participated in rater training ses-
sions prior to inclusion of patients into the study and
had received rater certiﬁcation were allowed to rate
patients. Patient ratings were assessed by the same
investigator at each visit, whenever possible.
Allocation to treatment
The medication was given as capsules of identical ap-
pearance. Patients who met the selection criteria at the
baseline visit were assigned to double-blind treatment
according to a computer-generated randomization list.
The details of the randomization series were unknown
to any of the investigators and were contained in a set
of sealed opaque envelopes. At each study site,
sequentially enrolled patients were assigned the low-
est randomization number available in blocks of four.
All investigators, study personnel and participants
were blinded to treatment assignment for the duration
of the entire study. The randomization code was bro-
ken for one patient (accidentally) who had completed
the study before this was discovered, and was there-
fore not withdrawn from the study.
Analysis sets
All safety analyses were based on the all-patients-
treated set (APTS), comprising all randomized
patients who took at least one dose of study medi-
cation. All eﬃcacy analyses were based on a modiﬁed
intent-to-treat set (ITT) – the full-analysis set (FAS),
comprising all patients in the APTS who had at least
onevalidpost-baselineMADRStotalscoreassessment.
Power and sample size calculations
It was planned to randomize a minimum of 384
patients with a DSM-IV-TR diagnosis of a major de-
pressive episode (MDE) into the double-blind period
of the study. With 96 patients in each treatment group
and a standard deviation (S.D.) of 9 points, the power
to detect a true treatment eﬀect of 3.7 points on the
MADRS total score at week 6, using last observation
carried forward (LOCF), would be 80%.
Primary eﬃcacy analysis
Four hypotheses were part of the primary eﬃcacy
analysis, which was fully adjusted for multiplicity
using a hierarchical testing procedure at the 5% level
of signiﬁcance as long as the previous hypothesis was
rejected. The order of testing was: no diﬀerence be-
tween the 10 mg dose vs. placebo at week 6, no diﬀer-
ence between 5 mg vs. placebo at week 6, no diﬀerence
between 10 mg dose vs. placebo at week 1, and ﬁnally
no diﬀerence between 5 mg dose vs. placebo at week 1.
The statistical model was an analysis of covariance
(ANCOVA) of the change from baseline in MADRS
total score (FAS, LOCF) with treatment and site as
ﬁxed factors and the baseline MADRS score as a co-
variate. The primary eﬃcacy analysis was repeated on
observed cases (OC) data, using both an ANCOVA
and a mixed model for repeated measurements
(MMRM).
Secondary eﬃcacy analysis
Prospectively deﬁned secondary clinician-rated vari-
ables were: MADRS total score, 24-item Hamilton
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Clinical Global Impression – Improvement (CGI-I)
and Clinical Global Impression – Severity (CGI-S)
scores (Guy, 1976), Hamilton Anxiety (HAMA) total
score (Hamilton, 1959), remission [deﬁned as MADRS
f10, 17-item HAMD (HAMD17) f7 or as a CGI-S
score f2] and response (deﬁned as o50% decrease
from baseline in MADRS or HAMD24 total score, or a
CGI-I score f2) at all time points.
The change from baseline to each visit in all the
secondary eﬃcacy variables, except response and re-
mission, was analysed using an ANCOVA, adjusting
for baseline score, site, and treatment, using both
OC and LOCF data. For CGI-I, the baseline CGI-S
score was used for adjustment. The change from
baseline to each visit in all the secondary eﬃcacy
variables, except response and remission, was also
analysed using MMRM to compare the treatment
groups over all assessment points simultaneously
using OC data.
Response and remission rates for each visit were
evaluated using Fisher’s exact test. The CGI-S and
CGI-I scores were analysed at the last visit (OC and
LOCF) using ANCOVA. Unless otherwise stated, the
terms ‘signiﬁcant’ and ‘signiﬁcantly’ refer to statisti-
cal signiﬁcance at the 5% level, two-sided. Eﬃcacy
analyses that were not multiplicity-controlled were
considered secondary. The principal statistical soft-
ware used was SAS
1 version 9.1 (SAS Institute Inc.,
USA).
Tolerability assessments
Each patient was asked a non-leading question
(such as, ‘how do you feel?’) at each visit, starting
at baseline. All AEs (including any change in concur-
rent illnesses or new illnesses) either observed by
the investigator or reported spontaneously by the
patient were recorded. AEs were coded using the
lowest level term according to the Medical Dictionary
for Regulatory Activities, version 10.0. The time to
withdrawal due to AEs was analysed using the Cox
model. The incidences of individual AEs were com-
pared between the treatment groups using Fisher’s
exact test.
As a post-hoc analysis, the safety database was
searched at preferred-term and verbatim-term level
for possible suicide-related AEs, as described by the
FDA (Laughren, 2006).
Results
Patient baseline characteristics
The APTS comprised 426 patients (placebo, 105;
venlafaxine, 113; 5 mg Lu AA21004, 108; 10 mg Lu
AA21004, 100) (Fig. 1). Slightly more patients than
planned were enrolled in the study, raising the power
from 80% to 84%. There were no clinically relevant or
statistically signiﬁcant diﬀerences between the treat-
ment groups in patient demographics or clinical
characteristics at baseline (Table 1). Patients had a
PBO
105
01 1 13
01 0 01
109 101 429 114
105 108 100 426 113
105 108 100 425 112
87 98 82 360 93
Patients
randomised
Not treated
Patients
treated
No MADRS
assessment
ITT
Patients
withdrawn
Patients
completed
Ven 225 Lu AA21004 5 Lu AA21004 10 Total
AEs      4
LoE      6
Other   8 
AEs       16
LoE      2
Other   2 
AEs      3
LoE      6
Other   1 
AEs      7
LoE      3
Other   8 
AEs      30
LoE      17
Other   18
Fig. 1. Flow chart of patient disposition. AE, Adverse events, ITT, intention to treat; LoE, lack of eﬃcacy; MADRS,
Montgomery–A ˚ sberg Depression Rating Scale; PBO, placebo; Ven 225, venlafaxine XR 225 mg.
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and 92.0% were Caucasian.
The mean baseline MADRS total score was 34.0,
indicating a severely depressed patient population,
consistent with the mean CGI-S score of 5.1. Patients
were diagnosed with their ﬁrst MDE y10 yr prior to
enrolment. Between 74% and 80% of the patients in
each treatment group had had a previous MDE and
their current episode had started about 5 months prior
to enrolment (Table 1). There was a substantial level of
anxiety symptoms, as indicated by a mean baseline
HAMA total score of 22.2. About 40% (range 36–41%)
of the patients in each treatment group had a concur-
rent medical condition. The number of patients taking
zolpidem, zopiclone, or zaleplon prescribed episodi-
cally for insomnia was similar for placebo (n=3),
venlafaxine (n=6), 5 mg Lu AA21005 (n=3), and
10 mg Lu AA21005 (n=3). Between 21% and 33% of
the patients took concomitant medication that they
continued with, and 26–29% commenced concomitant
medication during the study.
Withdrawals from the study
The withdrawal rate due to all reasons during the
entire study was 15% (Fig. 1), ranging from 9% (5 mg
Lu AA21004) to 18% (venlafaxine and 10 mg Lu
AA21004). More than 80% of the patients in each
treatment group completed the study (Fig. 1). There
was a slightly larger proportion of patients who
completed the study in the 5 mg Lu AA21004 group
than in the placebo, 10 mg Lu AA21004, or venlafaxine
groups. The proportions of patients who withdrew
due to AEs was statistically signiﬁcantly diﬀerent
between venlafaxine and placebo, but not between the
Lu AA21004 groups and placebo. There was an even
distribution of withdrawals for any reason over time
and no statistically signiﬁcant diﬀerences between
the treatment groups, between men and women, or
between patients aged f50 or >50 yr. The median
compliance with study medication was 98%.
Eﬃcacy
Primary endpoint
On the pre-deﬁned primary eﬃcacy endpoint, both
doses of Lu AA21004 were statistically signiﬁcantly
(p<0.0001) superior to placebo in mean change from
baseline in MADRS total score at week 6 (FAS, LOCF),
with mean treatment diﬀerences to placebo of 5.9
(5 mg) and 5.7 (10 mg) points (Table 2) in a multi-
plicity-controlledanalysis.Thesediﬀerencestoplacebo
correspond to a standardized eﬀect size (Cohen’s
d) of 0.56 (5 mg) and 0.54 (10 mg). Venlafaxine was
also statistically signiﬁcantly (p<0.0001) superior to
placebo at week 6, with a mean treatment diﬀerence to
placebo of 6.4 points (LOCF). The estimated treatment
diﬀerences and nominal p values at week 6 obtained
from an analysis using MMRM were similar to those
Table 1. Baseline patient characteristics
Placebo
(n=105)
Lu AA21004
5m g( n=108)
Lu AA21004 10 mg
(n=100)
Venlafaxine
225 mg (n=113)
Women 69 (65.7%) 70 (64.8%) 66 (66.0%) 62 (54.9%)
Age (yr)
Mean¡S.D. 42.0¡10.9 43.8¡11.6 42.3¡13.1 45.0¡10.3
Range 20–61 20–64 18–65 21–63
Caucasian 93.3% 93.5% 89.0% 92.0%
Patients with ﬁrst MDE 20.0% 22.2% 26.0% 25.7%
Years since ﬁrst MDE¡S.D.1 0 ¡81 0 ¡89 ¡91 1 ¡9
Days since start of current MDE¡S.D. 176¡82 161¡60 163¡68 163¡68
Eﬃcacy scoresa (n=105) (n=108) (n=100) (n=112)
MADRS total score¡S.D. 33.9¡2.7 34.1¡2.6 34.0¡2.8 34.2¡3.1
HAMD24¡S.D. 29.7¡5.0 29.9¡5.4 29.3¡5.6 29.4¡5.0
HAMA total score¡S.D. 22.9¡5.9 21.7¡6.2 22.3¡5.6 22.0¡5.5
CGI-S¡S.D. 5.1¡0.7 5.2¡0.7 5.1¡0.7 5.2¡0.7
aBased on the full-analysis set: CGI-S, Clinical Global Impression – Severity; HAMA, Hamilton Rating Scale for Anxiety;
HAMD24, Hamilton Rating Scale for Depression (24 items); MADRS,Montgomery–A ˚ sberg Depression Rating Scale; MDE, major
depressive episode; S.D., standard deviation.
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Lu AA21004), 7.2¡1.4 (10 mg Lu AA21004), 7.6¡1.3
(venlafaxine), all p<0.0001] (Table 2). As a sensitivity
analysis, the non-parametric Kruskal–Wallis test
showed a statistically signiﬁcant diﬀerence between
the active treatments and placebo. The assumption of
homogeneity of variances across treatment groups
was conﬁrmed using Bartlett’s test (p=0.90). At week
1, with a diﬀerence from placebo in the MADRS total
score of 0.8 for 10 mg (p=0.2377) and 0.2 for 5 mg
(p=0.7489), none of the active treatments separated
signiﬁcantly from placebo.
Secondary eﬃcacy analyses
MADRS
The mean MADRS total score decreased in all active
treatment groups from 34.1 at baseline to y13.4 in the
LOCF analysis and to y10.9 in the OC analysis at
week 6. For Lu AA21004, a statistically signiﬁcant
diﬀerence compared to placebo in the change from
baseline in MADRS total score, in favour of Lu
AA21004, was seen from week 2 (10 mg) or week 3
(5 mg) onwards (LOCF and OC). For venlafaxine, a
statistically signiﬁcant diﬀerence to placebo was seen
from week 2 (OC) or week 3 (LOCF) onwards (Fig. 2).
At week 6, the proportion of MADRS responders
(patients with o50% decrease in MADRS total score)
and remitters (MADRS score f10) was statistically
signiﬁcantly higher in all active treatment groups than
placebo (LOCF and OC) (Table 3). Single item analysis
at week 6 showed a statistically signiﬁcant advantage
for both doses of Lu AA21004 for 9 out of the 10 items
(except for ‘concentration diﬃculties’) relative to
placebo.
HAMD24
The mean HAMD24 total score decreased in all active
treatment groups from 29.5 at baseline to y11.7 in the
LOCF analysis and y9.7 in the OC analysis at week 6
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Fig. 2. Mean change from baseline in Montgomery–A ˚ sberg
Depression Rating Scale (MADRS) total scores (ANCOVA,
FAS, OC, over time) and LOCF (week 6). * p<0.05, ** p<0.01,
*** p<0.001 vs. placebo. FAS, Full-analysis set; LOCF, last
observation carried forward; OC, observed cases.
Table 2. Change from baseline in MADRS total score at week 6 (FAS)
Analysis Treatment group Mean¡S.E.
Diﬀerence
to placebo p value
LOCF,
ANCOVA
Placebo (n=105) x14.5¡1.0 – –
Lu AA21004 5 mg (n=108) x20.4¡1.0 x5.9¡1.4 <0.0001
Lu AA21004 10 mg (n=100) x20.2¡1.0 x5.7¡1.4 <0.0001
Venlafaxine (n=112) x20.9¡1.0 x6.4¡1.4 <0.0001
OC,
ANCOVA
Placebo (n=88) x16.6¡1.0 – –
Lu AA21004 5 mg (n=99) x22.3¡0.9 x5.7¡1.3 <0.0001
Lu AA21004 10 mg (n=83) x23.4¡1.0 x6.8¡1.3 <0.0001
Venlafaxine (n=95) x24.2¡0.9 x7.6¡1.3 <0.0001
MMRM Placebo (n=88) x15.7¡1.0 – –
Lu AA21004 5 mg (n=99) x21.3¡0.9 x5.6¡1.3 <0.0001
Lu AA21004 10 mg (n=83) x22.9¡1.1 x7.2¡1.4 <0.0001
Venlafaxine (n=95) x23.4¡0.9 x7.6¡1.3 <0.0001
FAS, Full-analysis set; LOCF, last observation carried forward; MADRS,
Montgomery–A ˚ sberg Depression Rating Scale; MMRM, mixed model repeated
measures; OC, observed cases; S.E., standard error of the mean.
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statistically signiﬁcant diﬀerence to placebo was seen
from week 1 onwards. For venlafaxine, a statistically
signiﬁcant diﬀerence to placebo was seen from week 2
(OC) or week 3 (LOCF) onwards. At week 6, the pro-
portion of HAMD24 responders (patients with o50%
decrease in HAMD24 total score) and remitters
(HAMD17 score f7) was statistically signiﬁcantly
higher in all active treatment groups compared to
placebo (LOCF and OC) (Table 3).
HAMA
The level of anxiety symptoms, as assessed by the
mean HAMA total score decreased in all active
treatment groups from y22 at baseline to y10.1 in the
LOCF analysis (Table 4) and y8.4 in the OC analysis
at week 6. For Lu AA21004, a statistically signiﬁcant
diﬀerence to placebo was seen in change from baseline
in HAMA total score from week 2 (10 mg, OC) or week
3 (LOCF and OC) onwards (Fig. 3). For venlafaxine,
a statistically signiﬁcant diﬀerence to placebo was seen
from week 3 (OC) or week 4 (LOCF) onwards.
CGI
The mean CGI-S score decreased in all active treat-
ment groups from y5.2 at baseline to y2.6 in the
LOCF analysis (Table 4) and y2.3 in the OC analysis
at week 6. The mean CGI-I score improved in all active
Table 3. Proportion (%) of responders and remitters at week 6 (FAS, mean)
Placebo
(n=105)
Lu AA21004
5m g( n=108)
Lu AA21004
10 mg (n=100)
Venlafaxine
225 mg (n=112)
LOCF OC LOCF OC LOCF OC LOCF OC
Response
o50% MADRS 45 52 67** 72** 68** 77** 72*** 83***
o50% HAMD24 40 45 72*** 78*** 69*** 78*** 72*** 83***
CGI-I f2 49 55 73*** 79** 76*** 86*** 77*** 88***
Remission
MADRS f10 27 32 49** 54** 49** 57** 55*** 64***
HAMD17 f7 28 33 47** 51* 45* 53** 46** 53*
CGI-S f2 26 31 45** 49* 50*** 59*** 54*** 62***
CGI-S, Clinical Global Impression – Severity; CGI-I, Clinical Global Impression – Improvement; HAMD17, Hamilton Rating
Scale for Depression (17 items); HAMD24, Hamilton Rating Scale for Depression (24 items); FAS, full-analysis set;
LOCF, last observation carried forward; MADRS, Montgomery–A ˚ sberg Depression Rating Scale; OC, observed cases.
*p<0.05, ** p<0.01, *** p<0.001 vs. placebo.
Table 4. Mean change from baseline in eﬃcacy variables at week 6, diﬀerence to placebo (FAS)
Eﬃcacy variable
LOCF, ANCOVA OC, ANCOVA MMRM
Lu AA21004
Ven
Lu AA21004
Ven
Lu AA21004
Ven 5 mg 10 mg 5 mg 10 mg 5 mg 10 mg
MADRS x5.9*** x5.7*** x6.4*** x5.7*** x6.8*** x7.6*** x5.6*** x7.2*** x7.6***
HAMD24 x5.3*** x5.3*** x5.1*** x5.0*** x5.9*** x6.3*** x5.2*** x6.3*** x6.1***
HAMA x3.3** x3.0** x2.9** x3.4*** x3.5*** x3.9*** x2.9** x3.8*** x3.5***
CGI-S x0.9*** x1.0*** x1.0*** x0.9*** x1.2*** x1.2*** x0.9*** x1.2*** x1.2***
CGI-I x0.6*** x0.6*** x0.7*** x0.6*** x0.7*** x0.9*** x0.6*** x0.8*** x0.9***
CGI-S, Clinical Global Impression – Severity; CGI-I, Clinical Global Impression – Improvement; FAS, full-analysis set; HAMA,
Hamilton Rating Scale for Anxiety; HAMD24, Hamilton Rating Scale for Depression (24 items); LOCF, last observation carried
forward; MADRS, Montgomery–A ˚ sberg Depression Rating Scale; OC, observed cases; MMRM, mixed model repeated
measures; Ven, venlafaxine.
Lu AA21004 for treatment of MDD 595treatment groups to y2.0 at week 6 (LOCF, Table 4).
For Lu AA21004, a statistically signiﬁcant diﬀerence to
placebo was seen in mean CGI-I score from week 1
(10 mg) or week 2 (5 mg) onwards (LOCF). For venla-
faxine, a statistically signiﬁcant diﬀerence to placebo
was seen from week 3 onwards (LOCF). At week 6, the
proportion of CGI responders (CGI-I f2) and CGI
remitters (CGI-S f2) was statistically signiﬁcantly
higher in all active treatment groups than placebo
(LOCF and OC) (Table 3).
Tolerability and safety
AEs
Since Lu AA21004 is a compound with a new mode of
action, its safety and tolerability proﬁle is described in
some detail below. During the 6-wk treatment period,
approximately three-ﬁfths of patients in the placebo
(61%) and 5 mg Lu AA21004 (68%) groups and ap-
proximately three-quarters of the patients in the 10 mg
Lu AA21004 (74%) and venlafaxine (75%) groups had
one or more AE. A total of 30 (7%) patients withdrew
due to AEs: four (4%) in the placebo group, three (3%)
in the 5 mg Lu AA21004 group, seven (7%) in the
10 mg Lu AA21004 group, and 16 (14%) in the venla-
faxine group. Only in the venlafaxine group, did stat-
istically signiﬁcantly more patients withdraw due to
AEs than in the placebo group (p=0.009). Seven
patients withdrew from the study due to nausea: three
(3%) in the 10 mg Lu AA21004 group and four (4%) in
the venlafaxine group.
AEs reported by o5% of patients during the 6-wk
treatment period are shown in Table 5. The most
common AEs reported in the active treatment groups
were nausea, headache, hyperhidrosis, and dry
mouth. For Lu AA21004, nausea (5 and 10 mg), hyper-
hidrosis (10 mg), and vomiting (10 mg) were the
only AEs reported with an incidence statistically sig-
niﬁcantly higher than placebo. For the majority of
patients reporting nausea, it was transient and mild or
moderate in intensity. In addition to nausea and hy-
perhidrosis, the incidence of dry mouth, constipation,
and anorgasmia were statistically signiﬁcantly higher
in the venlafaxine group than placebo group.
In all treatment groups, the majority of patients who
had AEs, had mild or moderate AEs. The incidence
of severe AEs was 4% in the placebo group, 6% in the
Lu AA21004 groups, and signiﬁcantly higher at 12%
in the venlafaxine group (p=0.026, Fisher’s exact).
Severe AEs reported by at least two patients in any Lu
AA21004 treatment group included: severe headache
by three patients (3%) in the 10 mg Lu AA21004 group
and two patients (1.9%) in the placebo group, and two
patients (1.9%) in the 5 mg Lu AA21004 group had
severe fatigue. In addition, severe AEs reported by
at least two patients in the venlafaxine group were:
severe nausea and severe vomiting, each reported by
two patients (1.8%), severe insomnia in four patients
(3.5%), severe dizziness in three patients (2.7%), and
severe hyperhidrosis in two patients (1.8%).
For patients treated with both Lu AA21004 doses,
the incidence of AEs related to sexual dysfunction
(anorgasmia, delayed ejaculation, erectile dysfunction,
decreased libido, impotence, abnormal organism,
abnormal sexual function) was at placebo level [1.9%
(5 mg) and 1.0% (10 mg) vs. 1.9% (placebo)]. In total,
23 AEs related to sexual dysfunction were reported by
18 patients, comprising seven women and 11 men. Of
the women (n=267), two were in the placebo group,
one from each of the Lu AA21004 groups, and three
from the venlafaxine group. Of the men (n=159),
all 11 were from the venlafaxine group, in which the
incidence of AEs related to sexual dysfunction was
statistically signiﬁcantly higher than placebo (12.4%
vs. 1.9%, p=0.0033, Fisher’s exact test). Two patients
withdrew due to AEs related to sexual dysfunction;
one due to anorgasmia and 1 due to delayed ejacu-
lation, both from the venlafaxine group.
No possibly suicide-related AEs were found in the
database search during the entire study. A decrease
in MADRS item 10 score (suicidal thoughts) from
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Fig. 3. Mean change from baseline in Hamilton Rating Scale
for Anxiety (HAMA) total scores (ANCOVA, FAS, OC, over
time) and LOCF (week 6). * p<0.05, ** p<0.01, *** p<0.001
vs. placebo. FAS, Full-analysis set; LOCF, last observation
carried forward; OC, observed cases. Some patients were
excluded due to the use of a non-validated scale in France.
596 E. Alvarez et al.baseline was seen in all treatment groups at all weeks.
A numerical superiority over placebo was seen in all
active treatment groups from week 2 onwards.
SAEs
No deaths occurred during the study. Three patients
had SAEs: two in the 10 mg Lu AA21004 group (one
patient with worsening of MDD, and one patient with
Varicella zoster infection) and one in the venlafaxine
group (brain tumour).
Vital signs, weight, clinical laboratory values, ECGs
No consistent trends were observed for vital signs,
weight, clinical laboratory values or ECG in the active
treatment groups, and there were no marked diﬀer-
ences between patients receiving active treatment and
those receiving placebo. The incidence of potentially
clinically signiﬁcant (PCS) values was generally low
and evenly distributed among the treatment groups
for vital signs, weight or clinical laboratory values, and
no patients withdrew due to a PCS value.
Allmeanvitalsignswerewithinthereferenceranges
and the mean changes from screening were generally
small [f2 mmHg (supine diastolic blood pressure),
f5 mmHg (supine systolic blood pressure), or
f4 bpm (supine pulse)].
The mean weight change from baseline to week 6
was f¡0.3 kg in the Lu AA21004 and placebo groups
and x0.8 kg in the venlafaxine group, which was not
considered to be clinically relevant. Weight gain
(o7%) was recorded for one placebo patient and three
patients in the 10 mg Lu AA21004 group, whereas
weight loss (o7%) was recorded for two patients in
the 10 mg Lu AA21004 group, and one patient in the
venlafaxine group. No patients withdrew due to
weight change.
The mean changes in clinical laboratory values were
small and similar between treatment groups and the
incidence of PCS values was generally <2% in any
treatment group for any laboratory test. No clinically
relevant abnormalities in ECG values were found after
administration of Lu AA21004.
Discussion
This is the ﬁrst double-blind, randomized, placebo-
controlled study to evaluate the eﬃcacy, safety and
tolerability of Lu AA21004 in patients with MDD. The
active reference, venlafaxine XR (225 mg), was in-
cluded with the purpose of validating the study
methodology and patient population, and was eﬀec-
tive on the primary eﬃcacy analysis. Both doses of
Lu AA21004 resulted in a signiﬁcant improvement
Table 5. Adverse events (AEs) with an incidence of o5% in any group in the 6-wk double-blind treatment period (APTS)
Preferred term
Placebo
(n=105)
Lu AA21004
5m g( n=108)
Lu AA21004
10 mg (n=100)
Venlafaxine
225 mg (n=113)
Patients with AEs 64 (61.0%) 73 (67.6%) 74 (74.0%) 85 (75.2%)
Nausea 10 (9.5%) 32 (29.6%)*** 38 (38.0%)*** 38 (33.6%)***
Headache 26 (24.8%) 23 (21.3%) 25 (25.0%) 32 (28.3%)
Hyperhidrosis 2 (1.9%) 3 (2.8%) 10 (10.0%)* 17 (15.0%)***
Vomiting 1 (1.0%) 2 (1.9%) 9 (9.0%)** 4 (3.5%)
Dry mouth 7 (6.7%) 8 (7.4%) 8 (8.0%) 19 (16.8%)*
Diarrhoea 5 (4.8%) 9 (8.3%) 7 (7.0%) 5 (4.4%)
Dizziness 8 (7.6%) 7 (6.5%) 7 (7.0%) 14 (12.4%)
Nasopharyngitis 9 (8.6%) 8 (7.4%) 7 (7.0%) 4 (3.5%)
Fatigue 6 (5.7%) 4 (3.7%) 6 (6.0%) 11 (9.7%)
Insomnia 5 (4.8%) 7 (6.5%) 6 (6.0%) 14 (12.4%)
Constipation 1 (1.0%) 1 (0.9%) 3 (3.0%) 11 (9.7%)**
Vision blurred 2 (1.9%) 2 (1.9%) 1 (1.0%) 6 (5.3%)
Anorgasmia 0 0 0 7 (6.2%)*
Ejaculation delayed (men)a 0 0 0 4 (7.8%)
Erectile dysfunction (men)a 0 0 0 4 (7.8%)
Tremor 3 (2.9%) 5 (4.6%) 0 6 (5.3%)
APTS, All-patients-treated set.
aNumber of men: n=36 (placebo), n=38 (5 mg), n=35 (10 mg), n=51 (venlafaxine).
*p<0.05, ** p<0.01, *** p<0.001 vs. placebo.
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It has been suggested (Moncrieﬀ & Kirsch, 2005) that
the diﬀerence in total scores for an active treatment
vs. placebo can be driven by a few single individual
items in a rating scale. However, this is not the case in
the present study, in which both doses of Lu AA21004
showed signiﬁcantly greater eﬃcacy than placebo on
nine of the 10 MADRS items.
There is a large diﬀerence to placebo for all active
treatment groups of about 5–6 points on the HAMD24
(which translates to y4 points on the HAMD17), which
is more than the y2 points on the HAMD17 seen in
FDA pivotal antidepressant studies (Kirsch et al. 2002).
This also conﬁrms the assay sensitivity of the studied
population, who were not only severely depressed,
but also had a substantial level of anxiety symptoms at
baseline. At week 6, the proportion of MADRS re-
sponders (patients with o50% decrease in MADRS
total score) and remitters (MADRS score f10) was
statistically signiﬁcantly greater in all active treatment
groups than in placebo (LOCF and OC). The diﬀerence
between active treatment and placebo of y6 points
on the MADRS translates into a clinically relevant
diﬀerence in response rates of between 22% and 32%
units, compared to an average of 16% units for anti-
depressants approved by the competent European
authorities (Melander et al. 2008). The robustness of
the results was also conﬁrmed by the signiﬁcantly
better outcome than placebo on HAMD24, HAMA,
CGI-I and CGI-S.
Several pharmacological mechanisms are likely to
account for the multimodal antidepressant action of
Lu AA21004. It has been estimated that an 80% occu-
pancy of the human SERT is achieved at standard
doses of SSRIs or SNRIs (Meyer, 2007). However,
5 mg Lu AA21004 occupies y40% of SERT sites,
suggesting the existence of additional mechanisms
involved in its therapeutic activity. Hence, SERT
blockade by SSRIs evokes a series of negative feedback
mechanisms that attenuate the increase in extracellular
(synaptic) concentration of 5-HT, including the acti-
vation of 5-HT1A and 5-HT1B autoreceptors on sero-
tonergic neurons (Artigas et al. 1996, 2001). The partial
agonist activity of Lu AA21004 at 5-HT1B receptors
may therefore help counteract the inhibition of
terminal 5-HT synthesis and release evoked by 5-HT1B
receptor activation. Likewise, its full agonist activity at
human 5-HT1A receptors expressed in cell lines is
predicted to evoke a rapid desensitization of 5-HT1A
autoreceptors (Haddjeri et al. 2009), thereby normal-
izing serotonergic cell ﬁring and 5-HT release. On the
other hand, given the presence of excitatory 5-HT3
receptors in GABAergic interneurons in cortical and
limbic areas (Morales et al. 1996; Puig et al. 2004), their
activation by 5-HT may induce a GABA-mediated in-
hibition of neurotransmitter release. In support of this
view, the 5-HT3 receptor antagonist ondansetron aug-
ments the increase of extracellular 5-HT in the ventral
hippocampus induced by the SSRI paroxetine (Mørk
et al. 2009). Moreover, blockade of 5-HT7 receptors
has been shown to produce rapid antidepressant-
like eﬀects in the rat in behavioural and electro-
physiological experimental paradigms (Mnie-Filali
et al. 2011). In addition to these eﬀects on the 5-HT
system, the systemic administration of Lu AA21004
increases the extracellular concentration of dopamine,
noradrenaline and acetylcholine (Haddjeri et al. 2009),
an eﬀect probably contributing to its antidepressant
activity.
Due to the proﬁle of Lu AA21004, a hierarchical
procedure was used to test for onset of action at
week 1. Although not signiﬁcant on the MADRS, Lu
AA21004 displayed onset of antidepressant action,
with signiﬁcant improvement vs. placebo at week 1
onwards for both doses on HAMD24, and for the 10 mg
dose on CGI-I.
The proportion of patient withdrawals has been
used in recent years as an indirect index of drug
eﬀectiveness in the real world (Kahn et al. 2008;
Lieberman et al. 2005; Trivedi et al. 2006). The analysis
of withdrawal rates in patients treated with Lu
AA21004 indicates a better tolerability proﬁle com-
pared to the active reference, venlafaxine. Compared
to placebo, signiﬁcantly more patients withdrew due
to AEs only in the venlafaxine group.
The most common AEs reported in the active treat-
ment groups were nausea, headache, hyperhidrosis,
and dry mouth. No possibly suicide-related AEs were
found. No consistent trends were observed for vital
signs, weight, clinical laboratory values or ECG in the
active treatment groups, and there were no marked
diﬀerences between patients receiving active treat-
ment and those receiving placebo.
Sexual dysfunction during antidepressant treat-
ment is one of the main reasons for the lack of com-
pliance (Kennedy & Rizvi, 2009). According to the
present data, the incidence of spontaneously reported
AEs related to sexual dysfunction was similar to
placebo in patients treated with either dose of Lu
AA21004. In the venlafaxine group, the incidence of
AEs related to sexual dysfunction was signiﬁcantly
higher than that of placebo (12.4% vs. 1.9%). Unlike
SSRIs, Lu AA21004 also displays moderate to high
aﬃnity for 5-HT1A, 5-HT1B, 5-HT3 and 5-HT7 receptors
(see above). There is limited information on the role of
these receptors on sexual drive, although the increase
598 E. Alvarez et al.in plasma testosterone levels evoked in male rats by
the proximity of female rats is further enhanced by
the selective 5-HT3 antagonist ondansetron, which
suggests that 5-HT3 receptor blockade may lead to an
enhanced sexual drive (Amstislavskaya & Popova,
2004).
The generalizability of results from this study to the
broad population of depressed patients, like most
randomized controlled trials, is limited by the in-
clusion and exclusion criteria. Patients aged <18 yr or
>65 yr were not included, nor were patients with
speciﬁed psychiatric or medical comorbidities, or
patients at risk of suicidal behaviour, nor those with
treatment-resistant depression or with mild to mod-
erate depression. The titration of venlafaxine XR, from
75 mg to 225 mg over 7 d, was according to the manu-
facturer’s instructions. Only one patient treated with
venlafaxine withdrew in the ﬁrst week of treatment,
indicating that there was no bias due to early with-
drawals in this treatment arm.
In conclusion, treatment with 5 mg and 10 mg Lu
AA21004 for 6 wk in this proof-of-concept study was
well tolerated and eﬃcacious in reducing depressive
and anxious symptoms in patients with MDD.
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